Free Trial

Arcus Biosciences (RCUS) Competitors

Arcus Biosciences logo
$9.60 -0.01 (-0.10%)
As of 02:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RCUS vs. SRRK, ACAD, PTCT, ZLAB, ACLX, VKTX, SWTX, AAPG, PTGX, and MLTX

Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Arcellx (ACLX), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Arcus Biosciences vs. Its Competitors

Scholar Rock (NASDAQ:SRRK) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Scholar Rock had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for Scholar Rock and 3 mentions for Arcus Biosciences. Scholar Rock's average media sentiment score of 1.40 beat Arcus Biosciences' score of 0.39 indicating that Scholar Rock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcus Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Scholar Rock has higher earnings, but lower revenue than Arcus Biosciences. Scholar Rock is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$33.19M110.14-$246.29M-$2.53-15.22
Arcus Biosciences$258M3.94-$283M-$4.19-2.29

Scholar Rock currently has a consensus target price of $44.14, indicating a potential upside of 14.66%. Arcus Biosciences has a consensus target price of $21.29, indicating a potential upside of 121.73%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
Arcus Biosciences
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Scholar Rock has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. Arcus Biosciences' return on equity of -70.58% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -118.22% -82.01%
Arcus Biosciences -258.94%-70.58%-32.97%

Scholar Rock has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Summary

Scholar Rock beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCUS vs. The Competition

MetricArcus BiosciencesMED IndustryMedical SectorNYSE Exchange
Market Cap$1.02B$3.06B$5.61B$20.89B
Dividend YieldN/A2.39%4.71%3.60%
P/E Ratio-2.2921.5127.9028.01
Price / Sales3.94205.32392.4668.85
Price / CashN/A42.5736.3223.29
Price / Book1.818.338.394.56
Net Income-$283M-$55.06M$3.25B$993.24M
7 Day Performance-1.49%-2.37%-1.61%-1.58%
1 Month Performance17.50%15.92%9.08%3.09%
1 Year Performance-39.16%5.53%35.49%9.26%

Arcus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCUS
Arcus Biosciences
1.5195 of 5 stars
$9.60
-0.1%
$21.29
+121.7%
-39.4%$1.02B$258M-2.29500Upcoming Earnings
Gap Up
SRRK
Scholar Rock
3.3055 of 5 stars
$41.12
+1.0%
$42.67
+3.8%
+307.3%$3.87B$33.19M-16.25140News Coverage
Positive News
Upcoming Earnings
Analyst Forecast
Gap Up
ACAD
ACADIA Pharmaceuticals
4.0988 of 5 stars
$22.28
-1.2%
$27.88
+25.1%
+20.7%$3.78B$957.80M16.26510News Coverage
Upcoming Earnings
Analyst Revision
PTCT
PTC Therapeutics
4.4581 of 5 stars
$47.86
+0.5%
$65.00
+35.8%
+51.6%$3.78B$806.78M7.351,410Trending News
Analyst Forecast
Analyst Revision
ZLAB
Zai Lab
3.0796 of 5 stars
$34.66
+3.2%
$54.28
+56.6%
+115.6%$3.73B$398.99M-13.921,869Gap Down
ACLX
Arcellx
2.456 of 5 stars
$69.39
+2.7%
$111.23
+60.3%
+12.7%$3.72B$107.94M-23.2180Positive News
Gap Up
VKTX
Viking Therapeutics
4.4565 of 5 stars
$31.94
-0.2%
$87.15
+172.9%
-46.3%$3.60BN/A-27.7720Trending News
Earnings Report
Analyst Revision
SWTX
SpringWorks Therapeutics
0.6383 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230Upcoming Earnings
AAPG
Ascentage Pharma Group International
N/A$39.71
-1.7%
N/AN/A$3.52B$134.35M0.00600Gap Down
PTGX
Protagonist Therapeutics
1.3717 of 5 stars
$55.22
-0.5%
$66.10
+19.7%
+41.7%$3.44B$434.43M73.63120News Coverage
Upcoming Earnings
Insider Trade
MLTX
MoonLake Immunotherapeutics
2.8288 of 5 stars
$53.57
+0.9%
$74.50
+39.1%
+21.4%$3.40BN/A-23.292News Coverage
Upcoming Earnings
Analyst Upgrade

Related Companies and Tools


This page (NYSE:RCUS) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners